Medical Therapy of Active Ulcerative Colitis

Conclusion: There is a great need for additional innovative therapies, especially in cases of primary non-response or secondary loss of response to anti-TNF antibodies. New small molecules (Janus kinase inhibitors) are promising with an acceptable safety profile and efficacy in UC. Further, strategies that target the intestinal microbiome are currently considered for patients with active or relapsing UC, and may in the future open up new therapeutic options.Viszeralmedizin
Source: Viszeralmedizin - Category: Gastroenterology Source Type: research